NasVax engages in the development and commercialization of proprietary polycationic lipid-based molecules, designed to improve vaccines either by formulating an intranasal carrier platform for painless administration of vaccines or by serving as an adjuvant platform for superior response of the body's immune system.

The Company's lead application, a needle-free, intranasal influenza vaccine has advanced from bench to clinical trials in less than 18 months.
NasVax Ltd. (NSVX) is a public bio-pharma company traded on the Tel Aviv Stock Exchange (TASE).